Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa
- PMID: 847296
Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa
Abstract
Rats treated chronically with dopamine receptor blockers were found to have an increase in striatal 3H-dopamine binding and adenylate cyclase activity as manifestations of receptor supersensitivity. Both the increase in binding and in adenylate cyclase activity were reversed by chronic 1-dopa treatment, presumably by increasing the supply of specific ligand (dopamine). The use of deliberate receptor sensitivity manipulation may be useful as a treatment for conditions involving disturbances in receptor sensitivity such as tardive dyskinesia and insulin resistant diabetes.
Similar articles
-
Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.J Pharmacol Exp Ther. 1990 Jun;253(3):950-6. J Pharmacol Exp Ther. 1990. PMID: 2162953
-
Dopamine receptor changes in response to prolonged treatment with L-dopa.J Neural Transm Suppl. 1986;22:33-45. J Neural Transm Suppl. 1986. PMID: 2946813
-
Chronic sulpiride treatment produces supersensitivity of striatal adenylate cyclase to dopamine in sexually immature or adult castrated rats.J Pharmacol Exp Ther. 1983 Mar;224(3):627-33. J Pharmacol Exp Ther. 1983. PMID: 6827485
-
Chronic pharmacological manipulation of dopamine receptors in brain.Neuropharmacology. 1987 Jul;26(7B):931-40. doi: 10.1016/0028-3908(87)90072-4. Neuropharmacology. 1987. PMID: 2889159 Review.
-
Vascular dopamine receptor as a model for other dopamine receptors.Adv Biochem Psychopharmacol. 1978;19:119-29. Adv Biochem Psychopharmacol. 1978. PMID: 358776 Review. No abstract available.
Cited by
-
Reduction of dopaminergic supersensitivity by a single dose of amphetamine.Naunyn Schmiedebergs Arch Pharmacol. 1980 Aug;313(2):131-3. doi: 10.1007/BF00498568. Naunyn Schmiedebergs Arch Pharmacol. 1980. PMID: 6106902
-
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94. doi: 10.1136/jnnp.68.5.589. J Neurol Neurosurg Psychiatry. 2000. PMID: 10766888 Free PMC article. Clinical Trial.
-
[3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment.Neurochem Res. 1980 Jun;5(6):641-51. doi: 10.1007/BF00964785. Neurochem Res. 1980. PMID: 7402434
-
Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.Psychopharmacology (Berl). 1987;93(2):218-22. doi: 10.1007/BF00179937. Psychopharmacology (Berl). 1987. PMID: 3122254
-
Enhancement of haloperidol-induced increase in rat striatal or mesolimbic 3,4-dihydroxyphenylacetic acid and homovanillic acid by pretreatment with chronic methamphetamine.Psychopharmacology (Berl). 1981;74(4):316-20. doi: 10.1007/BF00432738. Psychopharmacology (Berl). 1981. PMID: 6794073
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources